Publications
Selected Publications:
1. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB and Dannenberg AJ. 1996. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res., 56:4424-4429.
2. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H and Dannenberg AJ. 1997. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res., 57: 1081-1085.
3. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H and Dannenberg AJ. 1997. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res., 57: 2890-2895.
4. Zhang F, Subbaramaiah K, Altorki N and Dannenberg AJ. 1998. Dihydroxy bile acids induce the transcription of cyclooxygenase-2. J. Biol. Chem., 273:2424-2428.
5. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM and Dannenberg AJ. 1998. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 273:21875-21882.
6. Subbaramaiah K, Chung WJ and Dannenberg AJ. 1998. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of ERK/JNK and p38 pathways. J. Biol. Chem., 273: 32943-32949.
7. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL and Dannenberg AJ. 1999. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 59:991-994.
8. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A and Dannenberg AJ. 1999. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem., 274:10911-10915.
9. Subbaramaiah K, Hart JC, Norton L and Dannenberg AJ. 2000. Microtubule interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 and p38 MAP kinase pathways. J. Biol. Chem., 275:14838-14845.
10. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K and Dannenberg AJ. 2001. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res., 7:429-434.
11. Subbaramaiah K, Lin DT, Hart JC and Dannenberg AJ. 2001. PPARg ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of AP-1 and CBP/p300. J. Biol. Chem., 276:12440-12448.
12. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K and Dannenberg AJ. 2001. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res., 7:3349-3355.
13. Zhang F, Altorki NK, Wu Y-C, Soslow RA, Subbaramaiah K and Dannenberg AJ. 2001. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats. Evidence for involvement of bile acids. Gastroenterology, 121:1391-1399.
14. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson P-J, Delellis RA, Subbaramaiah K and Dannenberg AJ. 2001. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res., 7:3971-3976.
15. Subbaramaiah K, Norton L, Gerald W, and Dannenberg AJ. 2002. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 277:18649-18657.
16. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AMC and Dannenberg AJ. 2002. Celecoxib, a selective cyclooxygenase-2 inhibitor, protects against human epidermal growth factor receptor 2(HER-2)/neu-induced breast cancer. Cancer Res., 62:5405-5407.
17. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW and Dannenberg AJ. 2003. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer. J. Clin. Oncol., 21:2645-2650.
18. Subbaramaiah K, Marmo TP, Dixon DA and Dannenberg AJ. 2003. Regulation of cyclooxygenase-2 mRNA stability by taxanes. Evidence for involvement of p38, MAPKAPK-2 and HuR. J. Biol. Chem., 278:37637-37647.
19. Dannenberg AJ and Subbaramaiah K. 2003. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell, 4:431-436.
20. Subbaramaiah K, Yoshimatsu K, Scherl E, Das KM, Glazier KD, Golijanin D, Soslow, RA, Tanabe T, Naraba H, and Dannenberg AJ. 2004. Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J. Biol. Chem., 279:12647-12658.
21. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton, J.A., Subbaramaiah K, Dannenberg AJ and Neugut AI. 2004. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA, 291: 2433-2440.
22. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K and DuBois RN. 2005. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacological targets for chemoprevention. J. Clin. Oncol., 23:254-266.
23. Moraitis D, Du B, De Lorenzo MS, Boye JO, Weksler BB, Cohen EG, Carew JF, Altorki NK, Kopelovich L, Subbaramaiah K and Dannenberg AJ. 2005. Levels of COX-2 are increased in the oral mucosa of smokers. Evidence for the role of EGFR and its ligands. Cancer Res, 65:664-670.
24. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT and Dannenberg AJ. 2005. Celecoxib inhibits prostate cancer growth: Evidence of a COX-2-independent mechanism. Clin Cancer Res, 11:1999-2007.
25. Du B, Altorki NK, Kopelovich L, Subbaramaiah K and Dannenberg AJ. 2005. Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: Evidence of a cyclic AMP-responsive element binding protein-dependent mechanism. Cancer Res., 65:5982-5988.
26. Gross ND, Boyle JO, Morrow JD, Williams MK, Moskowitz CS, Subbaramaiah K, Dannenberg AJ and Duffield-Lillico AJ. 2005. Levels of PGE-M, the major urinary metabolite of PGE2, are increased in smokers. Clin Cancer Res, 11:6087-6093.
27. Howe LR, Chang S, Tolle KC, Dillon R, Young LJT, Cardiff RD, Newman RA, Yang P, Thaler HT, Muller WJ, Hudis C, Brown AMC, Hla T, Subbaramaiah K and Dannenberg AJ. 2005. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 65: 10113-10119.
28. Otani T, Yamaguchi K, Scherl E, Du B, Tai HH, Greifer M, Petrovic L, Daikoku T, Dey SK, Subbaramaiah K and Dannenberg AJ. 2006. Levels of NAD -dependent15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease. Evidence for involvement of TNF-α. Am. J. Physiol. Gastrointest. Liver Physiol., 290:G361-G368.
29. Subbaramaiah K, Howe LR, Port ER, Brogi E, Liu CH, Hla T, Hudis C and Dannenberg AJ. 2006. HER-2/neu status is a determinant of mammary aromatase activity in vivo. Evidence for a COX-2-dependent mechanism. Cancer Res., 66:5504-11.
30. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D and Markowitz SD. 2006. 15-hydroxyprostaglandin deydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA, 103:12098-12102.
31. Fukata M, Chen A, Klepper A, Krishnareddy S, Thomas LS, Xu R, Inoue H, Arditi M, Dannenberg AJ and Abreu MT. 2006. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling and is important for proliferation and apoptosis in response to intestinal mucosal injury. Gastroenterology,131: 862-867.
32. Yang P, Chan D, Felix E, Madden T, Klein RD, Shureiqi I, Chen X, Dannenberg AJ and Newman RA. 2006. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids, 75:385-395.
33. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, and Forastiere AA. 2007. Secondary chemoprevention of Barrett’s esophagus with celecoxib. JNCI, 99:545-57.
34. Subbaramaiah, K and Dannenberg AJ. 2007. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins. Evidence of a corepressor/coactivator exchange. Cancer Res., 67:3976-85.
35. Felts AS, Ji C, Stafford JB, Crews BC, Kingsley PJ, Washington MK, Subbaramaiah K, Siegel BS, Young SM, Dannenberg AJ and Marnett LJ. 2007. Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology. ACS Chemical Biology, 2:479-483.
36. Du B, Leung H, Khan KMF, Miller CG, Subbaramaiah K, Falcone DJ and Dannenberg AJ. 2007. Tobacco smoke induces urokinase-type plasminogen activator and cell invasiveness: evidence for an EGFR-dependent mechanism. Cancer Res., 67:8966-72.
37. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH and Abreu MT. 2007. Toll-like receptor-4 (TLR4) promotes the development of colitis-associated colorectal tumors. Gastroenterology, 133: 1869-1881.
38. Subbaramaiah K, Hudis C, Liu CH, Hla T, and Dannenberg AJ. 2008. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J. Biol. Chem., 283: 3433-3444.
39. Hughes D, Otani T, Yang P, Newman RA, Yantiss RK, Altorki NK, Port JL, Yan M, Markowitz SD, Mazumdar M, Tai HH, Subbaramaiah K and Dannenberg AJ. 2008. NAD -dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev. Res. 1:241-249.
40. Felts A, Siegel BS, Young SM, Moth CW, Lybrand TP, Dannenberg AJ, Marnett LJ, and Subbaramaiah K. 2008. Structure-activity relationship of sulindac derivatives that activate peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition. J. Med Chem. 51:4911-4919.
41. Hughes D, Guttenplan JB, Marcus CB, Subbaramaiah K and Dannenberg AJ. 2008. HSP90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation. Cancer Prev. Res. 1:485-493.
42. Subbaramaiah K, Benezra R, Hudis C and Dannenberg AJ. 2008. Cyclooxygenase-2 derived prostaglandin E2 stimulates Id-1 transcription. Evidence for the role of cross-talk with EGFR. J. Biol. Chem. 283:33955-33968.
43. Kekatpure VD, Dannenberg AJ, and Subbaramaiah K. 2009. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J. Biol. Chem., 284:7436-7445.
44. Duffield-Lillico AJ, Boyle JO, Zhou K, Ghosh A, Butala GS, Subbaramaiah K, Newman RA, Morrow JD, Milne GL and Dannenberg AJ. 2009. Levels of prostaglandin E metabolite and leukotriene E4 are increased in the urine of smokers. Evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev. Res. 2:322-9.
45. Antonarakis ES, Heath EI, Walczak JR, Nelson WG, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW and Carducci MA. A randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J. Clin. Oncol., in press.
